1. 113P A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer. (15th December 2019) Authors: Kotecki, N; O'Neil, B; Jalal, S; Massard, C; Wallin, J; Szpurka, A; Wang, D; Galvao, V Regnier; Xia, M S; Crowe, K; Geeganage, S; Doman, T; Gandhi, L; Xu, X; Bendell, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗